Advanced search
Publication Cover
Biomarkers in Medicine Volume 1, 2007 - Issue 4
Submit an article Journal homepage
77
Views
0
CrossRef citations to date
0
Altmetric
Review

Conventional and New Emerging Prognostic Factors in Breast Cancer: An Update

Andrea Nicolini1 University of Pisa,Department of Internal Medicine,Via Roma 67,56126Pisa,Italy.Correspondence[email protected]
,
Paola Ferrari2 [email protected]Correspondence[email protected]
,
Andrea Cavazzana3 University of Pisa,Department of Oncology,Via Roma 67,56126Pisa,Italy.Correspondence[email protected]
,
Angelo Carpi4 University of Pisa,Department of Ageing & Reproduction,Via Roma 67,56126Pisa,Italy.Correspondence[email protected]
,
Piero Berti5 University of Pisa,Department of Surgery,Via Roma 67,56126Pisa,Italy.Correspondence[email protected]
&
Paolo MiccoliCorrespondence[email protected]
Pages 525-540 | Published online: 17 Dec 2007

Bibliography

  • Nystrom L , RutqvistLE, WallSet al.: Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet341(8851), 973–978 (1993).
  • Miller AB , BainesCJ, ToT, WallC: Canadian National Breast Screening Study: 2: Breast cancer detection and death rates among women aged 50 to 59 years.CMAJ147(10), 1477–1488 (1992).
  • Kerlikowske K , MigliorettiDL, BuistDS, WalkerR, CarneyPA: National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.J. Natl Cancer Inst.99(17), 1335–1339 (2007).
  • Parkin DM , BrayF, FerlayJ, PisaniP: Global Cancer statistics 2002.CA Cancer J. Clin.55(2), 74–108 (2005).
  • Jemal A , SiegelR, WardEet al.: Cancer statistics 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
  • Heimann R , HellmanS: Aging, progression, and phenotype in breast cancer.J. Clin. Oncol.16(8), 2686–2692 (1998).
  • Heimann R , HellmanS: Clinical progression of breast cancer malignant behavior: what to expect and when to expect it.J. Clin. Oncol.18(3), 591–599 (2000).
  • Hayes DF , BastRC, DeschCEet al.: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst.88(20), 1456–1466 (1996).
  • Koscielny S , TubianaM, LeMGet al.: Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination. Br. J. Cancer49(6), 709–715 (1984).
  • Rosen PR , GroshenS, SaigoPE, KinneDW, HellmanS: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.J. Clin. Oncol.7(3), 355–366 (1989).
  • Rosen PP , GroshenS, KinneDW, NortonL: Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.J. Clin. Oncol.11(11), 2090–2100 (1993).
  • Quiet CA , FergusonDJ, WeichselbaumRR, HellmanS: Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up.J. Clin. Oncol.13(5), 1144–1451 (1995).
  • Mirza AN , MirzaNQ, VlastosG, SingletarySE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.Ann. Surg.235(1), 10–26 (2002).
  • Williams C , BrunskillS, AltmanDet al.: Cost–effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol. Assess.10(34), 15–36 (2006).
  • Duffy SW , TabarL, FagerbergGet al.: Breast screening, prognostic factors and survival-results from the Swedish two county study. Br. J. Cancer64(6), 1133–1138 (1991).
  • Bergh J , NorbergT, SjogrenS, LindgrenA, HolmbergL: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.Nat. Med.1(10), 1029–1034 (1995).
  • Quiet CA , FergusonDJ, WeichselbaumRR, HellmanS: Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes.J. Clin. Oncol.14(12), 3105–3111 (1996).
  • Tabar L , FagerbergG, DayNE, DuffySW, KitchinRM: Breast cancer treatment and natural history: new insights from results of screening.Lancet339(8790), 412–414 (1992).
  • Contesso G , MouriesseH, FriedmanS, GeninJ, SarrazinD, RouesseJ: The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy.J. Clin. Oncol.5(9), 1378–1386 (1987).
  • Dalton LW , PageDL, DupontWD: Histologic grading of breast carcinoma. A reproducibility study.Cancer73(11), 2765–2770 (1994).
  • Elston CW , EllisIO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.Histopathology19(5), 403–410 (1991).
  • Simpson JF , GrayR, DresslerLGet al.: Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J.  Clin. Oncol.18(10), 2059–2069 (2000).
  • Frkovic-Grazio S , BrackoM: Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.J. Clin. Pathol.55(2), 88–92 (2002).
  • Volpi A , BacciF, ParadisoAet al.: Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod. Pathol.17(9), 1038–1044 (2004).
  • Goldhirsch A , GlickJH, GelberRD, CoatesAS, ThurlimannB, SennHJ; Panel members: meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.Ann. Oncol.16(10), 1569–1583 (2005).
  • Loges S , ClausenH, ReicheltUet al.: Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin. Cancer Res.13(1), 76–80 (2007).
  • Vailhe B , KappM, DietlJ, ArckP: Human first-trimester decidua vascular density: an immunohistochemical study using VE-cadherin and endoglin as endothelial cell markers.Am. J. Reprod. Immunol.44(1), 9–15 (2000).
  • Martin TA , WatkinsG, LaneJ, JiangWG: Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin.Histopathology46(4), 422–430 (2005).
  • Uzzan B , NicolasP, CucheratM, PerretGY: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis.Cancer Res.64(9), 2941–2955 (2004).
  • Grimes DA , SchulzKF: Bias and causal associations in observational research.Lancet359(9302), 248–252 (2002).
  • Lee JS , KimHS, KimYB, LeeMC, ParkCS, MinKW: Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast.Appl. Immunohistochem. Mol. Morphol.12(3), 205–210 (2004).
  • Mohammed RA , GreenA, El-ShikhS, PaishEC, EllisIO, MartinSG: Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis.Br. J. Cancer96(7), 1092–1100 (2007).
  • Zhou S , WangGP, LiuC, ZhouM: Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.BMC Cancer6, 231 (2006).
  • Byrnes K , WhiteS, ChuQet al.: High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann. Surg.243(5), 684–690; discussion 691–692 (2006).
  • Tsutsui S , InoueH, YasudaKet al.: Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res. Treat.98(3), 261–266 (2006).
  • Jang KS , HanHX, PaikSS, BrownPH, KongG: Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer.Cancer Lett.244(2), 203–210 (2006).
  • Nicolini A , CampaniD, MiccoliPet al.: Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case–control study. Int. J. Biol. Markers19(4), 275–281 (2004).
  • Braun S , PantelK, MullerPet al.: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med.342(8), 525–533 (2000).
  • Gebauer G , FehmT, MerkleE, BeckEP, LangN, JagerW: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up.J. Clin. Oncol.19(16), 3669–3674 (2001).
  • Gerber B , KrauseA, MullerHet al.: Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J. Clin.Oncol.19(4), 960–971 (2001).
  • Funke I , SchrautW: Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.J.  Clin. Oncol.16(2), 557–566 (1998).
  • Wiedswang G , BorgenE, KaresenRet al.: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol.21(18), 3469–3478 (2003).
  • Diel IJ , CoteRJ: Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.Cancer Treat. Rev.26(1), 53–65 (2000).
  • Cristofanilli M , BuddGT, EllisMJet al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.351(8), 781–791 (2004).
  • Stathopoulou A , VlachonikolisI, MavroudisDet al.: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.J.  Clin. Oncol.20(16), 3404–3412 (2002).
  • Braun S , NaumeB: Circulating and disseminated tumor cells.J.  Clin. Oncol.23(8), 1623–1626 (2005).
  • Pierga JY , BonnetonC, Vincent-SalomonAet al.: Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res.10(4), 1392–1400 (2004).
  • Slade MJ , SmithBM, SinnettHD, CrossNC, CoombesRC: Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer.J. Clin. Oncol.17(3), 870–879 (1999).
  • Schoenfeld A , KrugerKH, GommJet al.: The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur. J. Cancer33(6), 854–861 (1997).
  • Barbareschi M : Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: a review of the literature involving over 9000 patients.Appl. Immunohistochem. Mol. Morphol.4, 106–116 (1996).
  • Elledge RM , FuquaSA, ClarkGM, PujolP, AllredDC, McGuireWL: Prognostic significance of p53 gene alterations in node-negative breast cancer.Breast Cancer Res. Treat.26(3), 225–235 (1993).
  • Pharoah PD , DayNE, CaldasC: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.Br.  J.  Cancer80(12), 1968–1973 (1999).
  • Nicolini A , CarpiA, TarroG: Biomolecular markers of breast cancer.Front. Biosci.11, 1818–1843 (2006).
  • Daidone MG , SilvestriniR: Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer.J. Natl Cancer Inst. Monographs (30), 27–35 (2001).
  • Wenger CR , ClarkGM: S-phase fraction and breast cancer-a decade of experience.Breast Cancer Res. Treat.51(3), 255–265 (1998).
  • Clark GM , WengerCR, BeardsleeSet al.: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer71(6 Suppl.), 2157–2162 (1993).
  • Regan MM , VialeG, MastropasquaMG et al.: International Breast Cancer Study Group: re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J. Natl Cancer Inst.98(21), 1571–1581 (2006).
  • Klijn JG , BernsPM, SchmitzPI, FoekensJA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.Endocr. Rev.13(1), 3–17 (1992).
  • Fox SB , SmithK, HollyerJ, GreenallM, HastrichD, HarrisAL: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.Breast Cancer Res. Treat.29(1), 41–49 (1994).
  • Henderson IC , PatekAJ: The relationship between prognostic and predictive factors in the management of breast cancer.Breast Cancer Res. Treat.52(1–3), 261–288 (1998).
  • Ross JS : The HER2/neu gene and protein in breast cancer: methods of detection and clinical significance.J. Clin. Ligand Assay23, 21–32 (2000).
  • Revillion F , BonneterreJ, PeyratJP: ERBB2 oncogene in human breast cancer and its clinical significance.Eur. J. Cancer34(6), 791–808 (1998).
  • van‘t Veer LJ , PaikS, HayesDF: Gene expression profiling of breast cancer: a new tumor marker.J. Clin. Oncol.23(8), 1631–1635 (2005).
  • Sorlie T , PerouCM, TibshiraniRet al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
  • van‘t Veer LJ , DaiH, van deVijver MJet al.: Gene expression profiling predicts clinical outcome of breast cancer.Nature415(6871), 530–536 (2002).
  • van de Vijver MJ , HeYD, van tVeer LJet al.: A gene-expression signature as a predictor of survival in breast cancer.N. Engl. J. Med.347(25), 1999–2009 (2002).
  • Glas AM , FlooreA, DelahayeLJet al.: Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics7, 278 (2006).
  • Buyse M , LoiS, van‘tVeer Let al.: TRANSBIG Consortium: validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.J. Natl Cancer Inst.98(17), 1183–1192 (2006).
  • Naderi A , TeschendorffAE, Barbosa-MoraisNLet al.: A gene-expression signature to predict survival in breast cancer across independent data sets.Oncogene26(10), 1507–1516 (2007).
  • Ma Y , QianY, WeiLet al.: Population-based molecular prognosis of breast cancer by transcriptional profiling. Clin. Cancer Res.13(7), 2014–2022 (2007).
  • Sotiriou C , NeoSY, McShaneLMet al.: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA100(18), 10393–10398 (2003).
  • Park ES , LeeJS, WooHGet al.: Heterologous tissue culture expression signature predicts human breast cancer prognosis. PLoS ONE2(1), E145 (2007).
  • Paik S , ShakS, TangGet al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
  • Korkola JE , BlaveriE, DeVriesSet al.: Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer7, 61 (2007).
  • Oh DS , TroesterMA, UsaryJet al.: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol.24(11), 1656–1664 (2006).
  • Gianni L , ZambettiM, ClarkKet al.: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol.23(29), 7265–7277 (2005).
  • Hess KR , AndersonK, SymmansWFet al.: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol.24(26), 4236–4244 (2006).
  • Weigelt B , GlasAM, WesselsLF, WitteveenAT, PeterseJL, van tVeer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases.Proc. Natl Acad. Sci. USA100(26), 15901–15905 (2003).
  • Perreard L , FanC, QuackenbushJFet al.: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res.8(2), R23 (2006).
  • Mullins M , PerreardL, QuackenbushJFet al.: Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin. Chem.53(7), 1273–1279 (2007).
  • Schlemmer BO , SorensenBS, OvergaardJ, OlsenKE, GjerdrumLM, NexoE: Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.Scand. J. Clin. Lab. Invest.64(5), 511–522 (2004).
  • Labuhn M , VuaroqueauxV, FinaFet al.: Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int. J. Biol. Markers21(1), 30–39 (2006).
  • Lyng MB , LaenkholmAV, PallisgaardNet al.: Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array. Cell Oncol.29(5), 361–372 (2007).
  • Ein-Dor L , KelaI, GetzG, GivolD: Outcome signature in breast cancer: is there a unique set?Bioinformatics21, 171–178 (2005).
  • Dunkler D , MichielsS, SchemperM: Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?Eur. J. Cancer43(4), 745–751 (2007).
  • Clark GM , DresslerLG, OwensMA, PoundsG, OldakerT, McGuireWL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.N. Engl. J. Med.320(10), 627–633 (1989).
  • Fisher B , GunduzN, CostantinoJet al.: DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer68(7), 1465–1475 (1991).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.